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Requiem for gouty nephropathy
Principal discussant: LAURENCE H. BECK
Philadelphia Veterans Administration Medical Center and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
A 74-year-aid black man was admitted to the Philadelphia Veterans
Administration Medical Center because of pain in several joints. The
patient was retired from a rubber factory. He had smoked cigars but
stopped 8 years prior to admission. He did not drink alcoholic bever-
ages and denied "moonshine" ingestion.
He had been well until 24 hours prior to admission, when he
developed increasing pain and swelling in his right great toe, followed
by similar pain in both ankles and in his right elbow. He denied chills or
fever, and he gave no history of recent infections, lraoma, or dysuria.
He reported several similar episodes of right foot pain, especially at
night, over the last 3 or 4 years, but these attacks had always subsided
within 24 to 48 hours and had never involved other joints. lie also gave
a history of "degenerative arthritis" of the knees, for which his own
physician had given him ibuprofen, 600 mg 3 times a day.
The patient had been known to have hypertension for about 10 years,
and he was taking furosemide, 40 mg daily, and elonidine, I mg daily.
He had suffered a "small stroke" in 1978 with minimal residual
right-sided weakness. He was unaware of any renal disease, and there
was no family history of gout, hypertension, diabetes mellitus, or renal
disease.
At the time of admission, he was febrile (temperature, 102.8°F
orally). Blood pressure was 140/90 mm Hg; pulse, 96 and regular. He
was an obese, alert man complaining of pain in his ankles, foot, and
elbow. Funduscopic examination showed arteriovenoos nicking, The
cardiac apical impulse was moderately displaced to the left, and there
was a grade lily! holosystolic murmur radiating to the axilla. The right
foot was swollen, red, and tender, especially over the first metatarso-
phalangeal joint. There was also tenderness and swelling in both ankles
as well as in the right elbow. No tophi were present. Except for a mild
motor weakness in the right upper extremity, the rest of the physical
examination was normal.
Initial laboratory lests revealed the following: hemoglobin, 14.7 g/dl;
hematocrit, 45.7%; white blood cell count, 14,700/mm3 with 85% polys,
9% lymphocytes, and 6% monocytes. Sodium was 144 mmol/liter;
potassium, 3.7 mmol/liter; chloride, 102 mmol/liter; and C02, 24
mmol/liter. Blood glucose was 135 mg/dl; BUN, 20 mg/dl; and ereati-
nine, 2.5 mg/dl. Uric acid was 10.2 mg/dl; calcium was 9.0 mg/dl.
Urinalysis revealed a pH of 5.0, 1 + protein, negative glucose, and
negative heme; microscopic examination disclosed a few hyahne casts
and no crystals. Chest x-ray was normal except for slight eardiomegaly.
An electrocardiogram was normal.
Arthrocentesis on both ankle joints yielded thick fluid. White blood
cell counts of the joint fluid were 68,000/mm3 and 89,000/mm3, with 93%
polys. Gram stain was negative. Both fluids were loaded with
monosodium urate crystals outside and within the polymorphonoclear
lenkocytes.
The patient was treated with intravenous colchieine, followed by oral
colchicine. Ibuprofen was discontinued because of the renal insuffi-
ciency. A cephalosporin antibiotic was administered for 24 hoors ontil
cultures were found to be negative. Because the fever and joint pain
continued for 24 hours with the patient taking colchicine, he was given
a short course of prednisone; this regimen produced quick resolution of
the joint symptoms.
After ibuprofen was discontinued, serum creatinine remained at 2.4
to 2.6 mg/dl. On the seventh hospital day, while he was ingesting a
normal diet, creatinine clearance was 37 mI/mm, and a 24-hr urine
collection revealed a total uric acid excretion of 590 mg. Renal
ultrasound showed no hydronephrosis, no stones, and normal-sized
kidneys. The patient was discharged with plans to begin taking al-
lopurinol as an outpatient.
Discussion
DR. LAURENCE H. BECK (Chief, Medical Service, Philadel-
phia Veterans Administration Medical Center, and Professor of
Medicine, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania):
The viscera in time are so much injured, from the stagnation of
the morbific matter therein, that the organs of secretion no
longer perform their functions, whence the blood, overcharged
with vitiated humours, stagnates, and the gouty matter ceases
to be thrown upon the extremities as formerly, so that at length
death frees him from his misery.
Thomas Sydenham, 1683
A Treatise of the Gout and the Dropsy 11]
Although the "morbific matler" referred to by Sydenham
was not identified as uric acid until some 200 years later by
Alfred B. Garrod, Sydenham's description probably represents
one of the earliest accounts of what is now called gouty
nephropathy, or chronic uric acid nephropathy.
By 1960, the concept of a specific renal disease in gout had
become accepted, particularly through the work of John
Talbott, who stated:
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there is an abundance of clinical and pathological data to
implicate the kidney heavily in the pathogenesis of the most
important complication. . . . Deposition of urate crystals may
be followed by fibrosis as a sequel Laboratory evidence
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of renal involvement is a frequent finding in patients with gout.
The development of renal insufficiency was critical in 18 per
cent of the larger series and 25 per cent in the smaller series of
postmortem protocols [21.
In the past decade, however, the existence of chronic gouty
nephropathy has been challenged. The controversy is evident in
the 1986 version of an authoritative renal textbook. In the
chapter on urate metabolism and the kidney [31, Grantham and
Chonko state:
gouty nephropathy is a chronic form of interstitial
nephritis resulting from the prolonged deposition of sodium
urate crystals in the renal parenchyma. The distinctive his-
tologic features of gouty nephropathy are the presence of urate
crystals in the medulla and the surrounding giant cell reaction.
In the chapter on tubulointerstitial disease from the same text
[41, Cotran, Rubin, and Tolkoff-Rubin, on the other hand, state:
The very existence of chronic gouty nephropathy, i.e. a
chronic nephropathy specifically caused by deposition of urate
crystals in the kidney is controversial In summary, many
factors may contribute to chronic nephropathy in a patient
with gout.
The purpose of my discussion today will be to review the
evidence for and against the entity of gouty nephropathy,
focusing particularly on the pathogenetic role of hyperuricemia
per se and on the response of the renal insufficiency to agents
that lower uric acid. In reviewing the evidence, I also will make
brief mention of one well-established uric acid-related renal
syndrome, acute uric acid nephropathy, but will not discuss
another, uric acid nephrolithiasis.
Renal handling of uric acid
The renal handling of uric acid involves a complex 4-compo-
nent system in which uric acid is first filtered, then extensively
reabsorbed, followed by tubular secretion and postsecretory
reabsorption [51. Secretion and reabsorption are probably dis-
tributed coextensively throughout the proximal and, perhaps,
distal tubules of the mammalian kidney, thereby preventing an
inordinately high concentration of urate within the tubular
lumen at any single location.
Most patients with gout have normal excretion rates of uric
acid and yet maintain sustained hyperuricemia. This observa-
tion implies the presence of an inefficient mechanism for renal
tubular excretion of uric acid in these patients as compared with
normal individuals. Using the antituberculous drug pyrazin-
amide, which is thought to block renal tubular secretion of urate
completely, several investigators have studied the contribution
of secretion and reabsorption in the tubular handling of urate in
gouty patients. Although some question remains about the
specificity of the pyrazinamide suppression test, studies indi-
cate that for a given serum level of uric acid, patients with gout
have a lower rate of uric acid secretion than do normal
individuals [61. This defect, in essence, requires an increased
'preload" of uric acid in the serum in order for the daily
production of uric acid to be excreted by the gouty patient's
kidneys. This renal tubular defect appears to he the primary
cause of hyperuricemia in most gouty patients. Most patients
with gout, therefore, probably have luminal concentrations of
uric acid similar to those in normal individuals, whereas the
concentration on the peritubular (blood) side is elevated. If
renal urate deposition were to occur, it probably would be
initiated outside the tubular lumen.
In contrast, a minority of patients with gout, estimated to be
as low as 0 to 10% [7, 81 or as high as 25% [91, are "overproduc-
ers" of uric acid and excrete a larger-than-normal amount per
day in the urine. These overproducers apparently have normal
tubular urate dynamics [61, compared with normal individuals.
The hyperuricemia is due not to an intrarenal defect, but to
overproduction of uric acid by the body tissues. These individ-
uals therefore might be expected to have increased intraluminal
urate concentrations, so that if deposition were to occur, it
would begin within the lumen.
Experimental orate nephropathy
Except for the great apes and humans, all mammals have the
liver enzyme unease, which converts uric acid to the very
water-soluble product allantoin. As a result, most mammals
have low serum uric acid concentrations and do not suffer the
consequences of uric acid deposition.
This lack of an animal model has limited our understanding of
the renal effects of hyperuricemia and gout. In 1974, however,
a rat model of hyperuricemia with nephropathy was described.
Rats treated with oxonic acid, a potent unease inhibitor, and
then fed a diet high in uric acid, develop both hyperuricemia
and marked hyperuricosuria [10]. Within one week, virtually all
the rats develop evidence of renal disease, with decreased
inulin clearance. Micropuncture studies demonstrate decreased
single-nephron GFR associated with a twofold increase in
tubular hydrostatic pressure [Ill. Pathologic examination
shows numerous white streaks throughout the medulla and
pyramids caused by the intratubular deposition of uric acid and
urate crystals. Secondary tubular atrophy, inflammatory cell
infiltration, and, with time, interstitial fibrosis all have been
reported [10, 121.
Although the originators of the rat model consider it an
appropriate parallel to human gouty nephropathy," there are
several major differences. The rats do not develop arthritis,
even with prolonged administration of the artificial diet. More
important, the histologic findings in the kidney are quite dif-
ferent from those in "gouty nephropathy" in humans. In
humans with long-standing gout, urate deposits in the kidneys,
when they have been noted, generally are not located within the
tubules, but in the interstitium. A marked difference also exists
in the magnitude of the uric acid traffic through the nephron.
Ihe range of uric acid excretion by gouty humans is limited,
even the greatest "overproducers" excreting no more than
twice the normal daily amount. In the oxonic acid-uric acid rat
model, uric acid excretion is increased sevenfold over baseline
[10]. 'ihus this model is substantially different from the usual
patient with chronic gouty arthritis, whose daily uric acid
excretion is normal or only moderately increased. Furthermore,
the rapidity of development of the experimental disease con-
trasts shatply with the putative gouty kidney, in which changes
develop over years. The rat model seems much more appropri-
ate for evaluation of a well-defined clinical entity, acute uric
acid nephropathy, which I will discuss briefly.
Acute uric acid nephropathy
Acute uric acid nephropathy occurs primarily in patients with
lympho- and myeloproliferative diseases. The syndrome rarely
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occurs spontancously, but more commonly develops after
cytotoxic therapy for lymphoma or Icukemia. when there is
rapid cellular lysis. The lysis results in release of large amounts
of nucleic acids, which are quantitatively converted to uric acid
and must be excreted by the kidney. The serum uric acid
concentration rises suddenly to levels greater than 20 mg/dl.
Initially extremely marked uricosuria is present, often manifest
by showers of uric acid crystals in the urinary sediment.
Microscopic or gross hematuria occasionally is seen. Serum
creatinine rises quickly as in other forms of acute oliguric renal
failure and, if no intervention is undertaken, the renal failure
can become irreversible. The pathologic findings in the kidney
result from deposition of uric acid crystals in the collecting
ducts, renal pelvis, and ureters, which produce intrarenal (and
occasionally extrarenal) hydronephrosis 13, 141.
The diagnosis is usually obvious given the clinical setting of a
patient with a lymphoma or leukemia undergoing cytotoxie
therapy. But diagnosis can be more difficult in patients with the
spontaneous variety. In the latter setting, it has been suggested
that the urinary uric acid-to-ereatinine concentration ratio is
diagnostic if greater than 1.0 [15]. More recent critical evalua-
tion of this diagnostic test, however, has shown it to be poorly
specific; ratios this high also occur in patients with acute renal
failure associated with fever or jaundice, and in patients with
nonoligurie acute renal failure [161.
Aggressive therapy designed to increase urine flow and to
render the urine alkaline (thus increasing uric acid solubility)
has resulted in reversal of the syndrome in some patients with
acute uric acid nephropathy; most patients, however, require
prompt hemodialysis to remove the bulk of the excess uric acid
load [13]. This entity, of course, should be of interest mostly to
medical historians, because clinicians are now well aware that
the syndrome can be prevented in virtually all patients with
lympho- or myeloproliferative disorders by the use of al-
lopurinol and vigorous hydration.
C/ironic gouty' ncphropn thy
Despite geueral agreement about the pathogenesis of acute
uric acid nephropathy, controversy continues over the patho-
genesis and even the existence of gouty nephropathy in hu-
mans. I will review the historic evidence for this putative
disease and will present more recent approaches to the study of
its pathogenesis.
In a lengthy elinicopathologic review of the kidney in gout,
lalbott and Terplan traced the history of observations linking
gout with renal pathology hack to the 16th century writer
Mareelli Donati and, later, to Sydenham in the 17th century [21.
More detailed descriptions were provided by Castelaneau and
by Todd in the mid-lSOOs, hut the niost important observations
were those of Sir Alfred Garrod in the late 19th century. Garrod
was the first to note white streaks of material in the pyramids of
a gouty patient's kidneys and to identify the material as urate of
soda (sodium urate). Garrod indicated that the material was not,
as he had first thought, within the tubular lumina, but instead
was imbedded in fibrous tissue in the interstitial space.
In 1952, Modern and Meister reported 3 patients with gout
and renal insufficiency, declaring that they could define a
clinical entity that they called "the kidney of gout" [171. Their
"specific renal lesion of gout" was characterized clinically by
renal insuffieney, fixed urinary specific gravity, azotemia, nor-
mal blood pressure, and the absence of proteinuria or formed
elements in the urinary sediment. In the single autopsy per-
formed, they described renal tophi, tubular atrophy, and inter-
stitial fibrosis. One of the patients had suffered a cerebrovas-
eular accident and another had an electrocardiogram suggestive
of an old myocardial infarction.
In an attempt to define better the pathologic renal lesions of
gout and to develop clinieopathologie correlations, Talbott and
Terplan reviewed the pathology and autopsy protocols of 279
patients with gout from around the United States [21. They
believed that there was sufficient clinical information to make
such correlations in about two-thirds of the patients. Although
theirs was not a longitudinal study, they did have enough
information in some patients to comment on the rate of decline
of renal function, as determined by serum urea values.
Talbott and Terplan noted a variety of pathologic findings,
but the most common were pyelonephritie sears; intrarenal
tophi, often surrounded or obscured by stellate sears; arterial
sclerosis; and intersitital fibrosis. Although numerous discrep-
ancies existed between the clinical severity of the gout and the
severity of the pathology, in general those patients with severe
tophaeeous gout had the most abnormal renal pathology. Fur-
thermore, 50% of the patients with severe gout (16 of 32) were
listed as having died from uremia. 1 should note, however, that
most of these patients' dl5O had coronary artery disease, heart
failure, or hypertension in addition to severe gout. Although
diabetes mellitus is mentioned only rarely, blood glucose levels
were not reported. Although Talhott and Terplan had expected
a close correlation between the severity of the gouty diathesis
and the renal anormalities, they noted that "a consistent
correlation between the severity of the clinical symptoms and
the severity of renal disease was not present in each instance.
On the contrary, there were notable exceptions. Some patients
with severe renal disease suffered minimal artieular distress.
Also, severe tophaeeous gout was observed in a few eases with
minimal clinical evidence of renal insufficiency."
In a later pathologic study of 25 patients with primary gout
who underwent renal biopsies, Barlow and Beilin noted the
almost universal presence of nephroselerosis [18], whereas this
finding was present in only 46% of age-matched controls.
Interstitial inflammatory changes were infrequent. Although
these percutaneous biopsies rarely contained medullary tissue,
the authors nevertheless concluded that the most specific
finding in gouty nephropathy is crystalline deposits. They
indicated that these deposits can he found in 90% of gouty
kidneys and include mierocaleuti of uric acid in collecting duets
and needle-like urate crystals in medullary interstitial tissues,
frequently surrounded by inflammatory cells.
The specificity of urate deposits has been addressed recently
by Linnane, Burry, and Emmerson in Australia [19]. They
tound medullary urate deposits in 8% of 1733 autopsies, When
72 of these patients with deposits were computer-matched with
a similar number of controls withoot deposits, the authors
found an increased prevalence of gouty arthritis and of renal
insufficiency in those with the deposits. However, 86% of
patients with orate deposits had no history of gout. A similar
lack of specificity of renal orate deposits was noted by Verger
and colleagues, who found medullary tophi in the kidneys of 17
of 62 patients who died of chronic renal insufficiency [201. Only
4 of these patients had exhibited gout during life, and all 17 had
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another primary renal diagnosis. Medullary orate deposits
therefore cannot be taken as diagnostic for gout.
Despite the lack of evidence from pathologic studies of a
close correlation between the severity of the gouty diathesis
and the presence of renal disease, a pathogenetic sequence,
which I call the hyperuricemia-gouty nephropathy hypothesis,
has become established in many clinicians' and investigators'
thinking. This hypothesis proposes that hyperuricemia, over
time, causes deposits of uric acid and its salts within the
interstitium of the kidney, leading to secondary inflammation.
fibrosis, and ultimate renal insufficency (the putative gouty
nephropathy). For example, in 1975 Murray and Goldberg
reported 101 patients with chronic interstitial nephritis seen at
one hospital and attempted, by retrospective chart review, to
assign an etiologic diagnosis to each [21]. Although the thrust of
that study was to highlight the 20% of patients who seemed to
have analgesic abuse as the cause of the renal failure, 11% of
the patients were considered to have hyperuricemia as the
primary and only cause of interstitial renal disease, presumably
from gouty nephropathy.
Despite such reports, recent longitudinal studies of gouty
patients have shed new light on the hyperuricemia-gouty
nephropathy hypothesis. By observing a series of gouty pa-
tients over many years, Berger and Yu have contributed greatly
to resolving this controversy [22—25]. They systematically stud-
ied the renal hemodynamics of more than 600 gouty men, and
they have analyzed the factors associated with impaired renal
function.
In 1975 Berger and Yu described their observations on renal
abnormalities in several hundred gouty patients [22]; serial
studies were reported for 112 of them [23]. Inulin and PAH
clearances were carried out at least twice in each individual at
intervals of 7 to 12 years. For the purpose of analysis, the
patients were separated into several groups. Primary gout with
no associated diseases was present in 56 of the men. Approxi-
mately one-half of these patients were treated with uric acid-
lowering drugs, and normouricemia was maintained between
the two study periods; the other half remained hypcruricemic
throughout the observation period and were not treated with
specific drugs. Inulin clearance was 116 mI/mm in the success-
fully treated group and was unchanged at 115 mI/mm after a
mean of 11 years. In the group that remained hyperuricemic,
initial and final inulin clearances were 117 and 121 mI/mm,
respectively. Thus, in these relatively healthy men, hyperuri-
cemia and gout alone were not associated with any deteriora-
tion in renal function over a number of years, even when
hyperuricemia persisted.
A smaller group of 13 gouty men had no associated disease at
the time of the first study, hut they developed hypertension
thereafter. In these patients, at a mean followup of 10 years,
glomerular filtration rate fell from 126 to 94 mI/mm. Similarly, in
a group of 25 individuals with hypertension at presentation as
well as at followup, GFR was depressed initially at 79 mI/mm
and further decreased to 70 mI/mm after 8 years of followup.
The authors also assessed the effect on renal function of the
interaction of aging and gout. In 11 patients whose mean age
was 65 years during the first study, inulin clearance fell by
approximately 16%, regardless of whether the hyperuricemia
was treated.
The authors reported 5 young patients (mean age 33 years)
with "rapidly progressive" gout characterized by multiple tophi
and recurrent attacks despite aggressive therapy. There was a
strongly positive family history of gout in 4 of these men. When
studied serially, inulin clearance averaged 58 mI/mm at the time
of the first study and fell to 49 mI/mm after a mean interval of 7
years, in spite of allopurinol therapy.
From this early study 23], Berger and Yu concluded that
gout and hypcruricemia alone did not cause renal insufficiency,
but that the likeliest malefactor was the associated hyperten-
sion. In 1979 the authors expanded their observations to include
149 gouty patients studied serially over intervals as long as 22
years [24]. As noted in the first report, the mean inulin clear-
ance did not change significantly in younger patients with gout
and no associated diseases, whether hyperuricemia was con-
trolled or not. Similarly, in patients over the age of 50 years at
entry, the GFR fell slightly over 8 years, but the fall was similar
regardless of the serum uric acid concentration during the
interval.
In 27 patients other diseases became apparent during the
fullowup period. These other diseases included hypertension.
atherosclerotic cardiac disease, or cerebrovascular disease. In
sharp contrast to the patients with no associated diseases, inulin
clearance for this group decreased from 115 ml/min to 88
ml/miii, the fall being more prominent in those over the age of
50 and, to a lesser extent, in those whose gout had been present
for more than 10 years.
A third group of 38 patients already had associated disease or
nephropathy at the time of the first study. The mean inulin
clearance was 76 mI/mm at entry and decreased further with
time.
When all the data were subjected to analysis of variance, it
became apparent that hyperuricemia per se had no independent
adverse effect on renal function. The most important of the
factors analyzed was the presence of an associated medical
condition. Aging constituted a small independent effect; the
duration of gout also appeared to contribute, albeit minimally,
hut could not he confidently separated from the effects of aging.
In their most recent analysis, Yu and Berger expanded these
observations to include 624 patients with gout [251. Assigning
the patients to groups similar to those already described, and
applying the same analytic approach, the authors reached
similar conclusions for the group as a whole. The strongest
correlate for decreased inulin clearance was the presence of
hypertension, ischemic heart disease, or preexisting chronic
renal disease (such as glomerulonephritis, infectious pyelone-
phritis, or amyloidosis). Age and duration of gout again con-
tributed in a minor way to the decrease in renal function.
One might argue that these observations arc suspect because
of the selection bias in Berger and Yu's study. It is possible that
a systematic bias in selecting patients for hypouricemic treat-
ment was exercised that obscured a beneficial effect of therapy
or, conversely, that "protected" untreated patients from drug-
induced nephrotoxicity. However, the large size of the popula-
tion studied, the several physicians involved in caring for the
patients, and the remarkable degree of similarity among the
various groups argues against such an interpretation.
Important confirmation of Berger and Yu's conclusions
comes from studies on the West coast 126, 27], Using the vast
data base provided by the Kaiser-Permanente Medical Centers
in Oakland and San Francisco, Fessel evaluated the renal
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correlates and outcomes in more than 200 subscribers with
either asymptomatic hyperuricemia or gouty arthritis. The
methods were as follows: To study asymptomatic hyperurice-
mia, individuals were identified whose serum uric acid concen-
tration was 2 SD above the population-derived mean for age and
sex. These asymptomatie individuals were free of gout, renal
disease, hypertension, diabetes, and clinical evidence of ather-
osclerosis, and they were not taking thiazide or other diuretics.
Normouricemic control subjects were matched in all the above
respects. In the hyperuricemic group, 113 patients had a
followup evaluation at a mean interval of 8 years. Similarly, 168
patients with gout were identified and computer-matched with
an age-, sex-, race-, and city-matched control who had another,
benign condition. These matched pairs were then evaluated for
the development of azotemia, renal stones, evidence of arterio-
sclerosis, hypertension, and diabetes.
In the patients with asymptomatic hyperuricemia, azotemia
(defined as a serum creatinine concentration beyond 2 SD
above normal) developed in 1.8%; in the controls, azotcmia
occurred in 2.1%, not significantly different. The patients with
gout were divided into those who received uric acid-lowering
drugs and those who did not: 130 had received such drugs for a
mean duration of 8.8 years; 72 received no drugs for a mean of
6 years.* Of the untreated patients, 10% developed azotemia,
with the highest creatinine level being 2.1 mg/dl. Similarly, 10%
of treated patients (whose creatinine was normal at the begin-
ning of the study) developed azotemia; the highest value at the
end of followup was 2.4 mg/mI. The 13 patients who had
azotemia at the outset (all of whom were treated with hypouri-
cemic drugs) showed little deterioration of renal function over 7
years of followup.
Combining the asymptomatic hyperuricemie patients with
those with gout, the overall occurrence of azotemia was 3.1%,
compared with 0.5% for the controls. This difference was
statistically significant (F c 0.05). However, when the patients
with clinical evidence of arteriosclerosis, hypertension, and
diabetes were excluded, no significant difference in the occur-
rence of azotemia was found between the two groups.
Using data from the asymptomatic hyperuricemic patients,
Fesset then analyzed prospectively and hypothetically a cohort
of persons aged 20 through 29 years. Using a computer, he
projected these patients over 40 years of hypcruriccmia, to age
60 through 69. With these cross-sectional data, he then pre-
dicted the effect of sustained hyperuricemia on serum creatinine
at 3 SD and at 6 SD above normal. A rise of uric acid to 3 SD
above normal might be associated with a maximal increase in
women from 0.9 mg/dl at 20 to 29 years to 1 .4 mg/dl at 60 to 69
years. For men, the increase could be from 1.2 mg/dl to 1.8
mg/dl. A sustained increase of serum uric acid concentration to
6 SD beyond normal (greater than 10 mg/dl in women, 13 mg/dl
in men) could be associated with a maximal rise in serum
creatinine to 2.0 mg/dl in women and to 2.7 mg/dl in men by age
60 to 69.
One can conclude the following from these large studies: (I)
Development of serious renal insufficiency is uncommon in the
* The total exceeded 168 because some patients had a period of
non-treatment followed by a period of treatment and thereby were
counted in both groups.
overwhelming majority of patients with typical gout; (2) Many
years of sustained hyperuricemia are unlikely to lead to serious
renal insufficiency; (3) In patients with gout who develop renal
insufficiency, renal failure is always attributable to a complicat-
ing associated medical condition; and (4) Treatment with uric
acid-lowering drugs does not appear to hasten or to inhibit the
development of renal failure. It would be incorrect to conclude,
however, that there are no patients with uncomplicated gout
who have developed serious concomitant renal disease leading
to renal failure. As 1 noted before, Berger and Yu described 5
young men, all but one with a family history of gout, who had
rapidly progressive renal disease in the absence of hypertension
and despite aggressive therapy of the hyperuricemia. These
patients represent a small but important group of patients with
familial gout and renal disease.
Familial gout and renal disease
The first well-documented pedigree of familial hyperuri-
cemia, gout, and renal disease was reported in 1960 by Duncan
and Dixon [28]. The propositus was a 19-year-old laborer with
acute gouty arthritis who had hyperuricemia, hypertension, and
severe renal failure associated with bilaterally small kidneys.
All 7 of his first-degree relatives had hyperuricemia, and 5 of
them had renal failure. The paper contained no pathologic
description of the kidneys in any members of this kindred.
Since then, numerous reports have described kindreds with
the combination of hyperuricemia or gout, usually presenting at
an early age and often in both sexes, associated with progres-
sive renal failure over a few to several years [29—331. In most of
these families, the transmission appears to be autosomal dom-
inant, although in a few, the disease is manifest only in women
[31]. Several reports documented many years of hyperurieemia
prior to a decrease in GFR, and lcd to the hypothesis that these
patients were affected by hyperuricemic nephropathy that was
due to deposition of urate crystals in the interstitium, followed
by a chronic inflammatory and fibrotic reaction.
When pathologic tissue has been available for review in these
familial cases, most specimens have revealed either focal or
diffuse interstitial fibrosis, often with chronic inflammatory cells
and secondary tubular atrophy. It is interesting that, with
perhaps a single exception [31], urate crystals have not been
noted.
Most of these patients have been treated with uric acid-
lowering agents, most commonly allopurinol. Although a few
patients have had no change in serum creatinine over short
followup periods on allopurinol (as long as 18 months), renal
function has continued to deteriorate in the rest despite main-
tenance of normouricemia. Hypertension often has been re-
ported as a late consequence of the renal failure in these
patients with familial disease. But because most have devel-
oped the renal failure in the absence of hypertension or other
systemic disease, many authors have concluded that the
nephropathy is secondary to the hyperuricemia.
The absence of crystals in the renal tissue, coupled with the
failure to halt progression with control of hyperuricemia and
uric acid production, however, warrants an alternative hypoth-
esis. It seems likely that the interstitial renal disease is inherited
in most families as an autosomal dominant trait, and that
hyperuricemia is only a sensitive early indicator of renal in-
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volvement. Leumann and Wegmann, in reporting another fam-
ily in 1983, came to a similar conclusion [34].
The role of lead
I have reviewed the evidence suggesting that hyperuricemia
per se cannot be implicated in the renal failure that may
occasionally develop in patients with chronic gouty arthritis,
and that another condition, usually hypertension, is the more
likely cause of nephropathy except in those few with familial
disease. It is entirely possible, however, that an additional
confounding factor could be present in these patients with gout,
hypertension, and renal failure that could be responsible for the
entire syndrome. A candidate for such a factor is lead. Lead
nephropathy was recently reviewed in a Nephrology Forum
presented by Bennett [351, and I will examine the issue only
briefly here. It is clear that lead has been reponsible for several
epidemics of gout, often with renal failure, during the last few
centuries. These epidemics have included the "golden age of
gout" in 18th and 19th century England [36], the patients with
gout and renal failure in Queensland, Australia, during the first
part of this century [37], and currently the patients with
"moonshine"-induced saturnine gout in the southeastern
United States [38].
Wedeen and coworkers have suggested that environmental
chronic lead intoxication is common in male veterans in the
northeastern United States with gout or hypertension who also
have renal insufficiency [39]. A large proportion of the gouty
patients described by Talbott in his classic 1960 paper were also
veterans from the northeast [2]. Is it possible that some or many
of those patients, in whom the incidence of renal insufficiency
seems clearly higher than current estimates, were patients with
chronic lead nephropathy?
The possibility of lead nephropathy was considered in the
patient presented today, although he denied any moonshine
ingestion or occupational exposure. Two weeks following dis-
charge he was readmitted for a 3—day diagnostic lead chelation
study. Control 24—hour lead excretion was 130 jig; following
EDTA chelation, total lead excretion was 281 g, well within
normal limits. It was concluded that his renal failure was due to
nephrosclerosis from chronic hypertension.
Conclusion
Despite its hoary past, the existence of gouty nephropathy
does not stand up to modern scrutiny. Although mild interstitial
renal disease does occur in a small proportion of patients with
chronic gouty arthritis, the nephropathy generally results from
hypertension, vascular disease, or independent renal disease.
In some cases, it can be traced to lead intoxication. In addition,
some families with gout appear to have an autosomal dominant,
inherited nephropathy in which hyperuricemia is an early
manifestation of the renal disease. Although therapy with uric
acid-lowering drugs may be appropriate for prevention of
arthritis in many patients, one should not expect reversal of
progressive renal insufficiency, which is independent of the
hyperuricemia.
Questions and answers
DR. JOHN T. HARRINGTON (Chief, Department of Medicine,
Newlon-Wellesley Hospital, Newton Massachusetts): 1 believe
that the current incidence of gouty nephropathy, however
diagnosed, is quite low in patients entered in dialysis or
transplant registries. Could you comment on this?
DR. BECK: The incidence of chronic gouty nephropathy
reported as the cause of chronic renal failure in this country and
in the world has decreased from the time of Talbott's paper to
a low value, so that more recently even in gouty patients it is
said to occur in no more than 5% or 10% of patients. The
registries of chronic renal failure populations that I'm familiar
with do not list gouty nephropathy as a cause. I recently had a
chance to reevaluate some data supporting analgesic nephrop-
athy as a cause of chronic renal failure in renal dialysis
populations and, in doing so, was unable to find even a single
instance in which gouty nephropathy could be construed as the
cause. I should point out, however, that in a study that begins
with end-stage renal disease patients as a data base, it is difficult
to go back and ascertain the proximate cause of the renal failure
because of a lack of records, biopsies, and the common
manifestations that all patients show at the time of end-stage
renal disease.
DR. JEROME P. KASSIRER (Associate Chairman, Department
of Medicine, New England Medical Center Hospitals): What
impresses me is that 20 to 30 years ago, severe gout was a
common clinical entity. It was not at all unusual to see patients
with huge tophi in their earlobes and elbows, and with multiple
tophi eroding their bones and joints. This severe form of the
disease has all but vanished. Does therapy with allopurinol have
any bearing on our capacity to attribute renal disease to gout?
DR. BECK: I believe so. The virtual elimination of severe gout
today makes me a little hesitant in saying that there was not
such a thing as chronic uric acid nephropathy in those patients
who had such enormous body burdens of uric acid. On the other
hand, I think that over the same period that effective hypouri-
cemic therapy has been available, we have been doing much
better also in treating hypertension. As you know, patients with
chronic gouty arthritis traditionally carry with them the baggage
of the other diseases their families seem to inherit or develop:
hypertension, obesity, and diabetes mellitus. I think we have
certainly done better in treating hypertension and perhaps we
can attribute some of the decreased frequency of renal failure in
gouty patients to effective antihypertensive therapy.
DR. RONALD PERRONE (Division of Nephrology, NEMCII):
I'd like to ask you about the separation of hypertension in your
analysis. You spoke about hypertension as if it were an unre-
lated disease that might or might not be superimposed on the
course of chronic gout. To what extent is hypertension a
superimposed secondary effect, and to what extent is it a
marker of renal damage due to chronic gouty nephropathy?
DR. BECK: It is difficult to make that separation and, unfor-
tunately, the best way we can do it is by using a multivariate
approach, as did both of the groups I mentioned. Such a method
doesn't really speak to cause and effect, but rather to associa-
tions. On the other hand, it has been suggested recently, based
on a study of serum uric acid and hemodynamics in patients
with essential hypertension, that hyperuricemia is an early
marker of renal vascular disease due to the hypertension [40].
When one examines the studies available, it remains difficult
to separate gout and hypertension completely. I think the best
interpretation I can make is that the gouty patients who develop
hypertension and subsequent renal insufficiency probably rep-
resent either of two populations of patients: some are patients
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with gout who are also destined to develop essential hyperten-
sion, and thereby end up with two separate conditions, only one
of which (hypertension) leads to renal insufficiency. Others may
be a part of a family pedigree in which the two diseases are
linked genetically. Further, as I noted just now, some patients
with essential hypertension develop hyperuricemia (and gout)
as a consequence of the renal changes induced by the hyper-
tension. Despite this confusion, I feel relatively confident that
the gout itself or the hyperuricemia per se is not the proximate
cause of the renal insufficiency.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
NEMCH): About one-quarter of untreated patients with pri-
mary hypertension have hyperuricemia. Is it known whether
patients with newly diagnosed primary gout have, as a group, a
higher prevalence of hypertension compared with an appropri-
ately matched population? Does the prevalence of hypertension
change as a function of the duration of gout? Such information
could shed some light on the pathogenetic relationship between
hypertension and gout.
DR. BECK: it is an excellent suggestion, hut to my knowledge,
such temporal data have not been published. That information
might be able to be teased out of the primary Permanente data,
but as yet, such an analysis has not been done.
DR. JAMES STROM (Chief, Division of Nephrology, St. Eliz-
abeth's Hospital, Boston): When do you treat hypcruriccmia in
patients with chronic renal failure?
DR. BEcK: Hyperuricemia is common in chronic renal failure,
but gouty arthritis and tophi are rare [411. I have reviewed the
literature carefully looking for data that address the value of
treating the hyperuricemia of chronic renal failure. Unfortu-
nately, such studies are virtually nonexistent. The only con-
trolled prospective study I know of that evaluated the effect of
allopurinol versus placebo on renal function in patients with
moderate renal insufficiency was carried out by Rosenfeld [42].
He found that in normotensive and in hypertensive patients
with initial creatinine clearances between 40 and 80 mI/mm and
hyperuricemia, followed for 30 to 40 months, the changes in
creatinine clearance were similar in patients with allopurinol-
induced normouricemia compared with the placebo patients,
who remained hyperuricemic. Although less well controlled,
Yu and Berger made similar observations in that group of their
gouty patients who had underlying renal disease [251. There was
no difference in the rate of progression whether normouricemia
was achieved or not.
An additional reason to be less concerned with the hyperuri-
cemia in renal disease is that the total uric acid load presented
to the kidney decreases as renal failure progresses [43]. lhis
change occurs presumably because of increased intestinal uric
acid secretion and uricolysis,
Because uricosuric drugs lose their effectiveness once the
GFR falls to 20% of normal or less, one is left with only one
treatment option: using allopurinol chronically in patients with
chronic renal failure, for whom the therapy has not been shown
to produce a benefit, and in whom the likelihood of toxicity is
probably higher. I choose not to treat them.
DR. KASSIRER: Some patients with mild renal insufficiency,
particularly those receiving diuretics, develop gout. I)o you
recommend treating all patients who have renal failure with
drugs to prevent gout?
DR. BECK: The proportion of the patients with chronic renal
failure who do develop gout is extremely low, from 0.5% to
1.0% [41, 44]. Therefore, it is not appropriate to treat these
patients prophylactically; I would wait until they develop an
attack of gouty arthritis.
DR. PAUL KURTIN (Chief, Division of I'ediatric Nephrology,
NEMCH): Does the reduced uric-acid load of a low-protein diet
have any influence on the progression of renal disease?
DR. BECK: The data I have reviewed suggest that uric acid or
orate precipitation in the kidney does not contribute to the
deterioration of renal function in patients with gout, so I would
doubt that the low uric acid load resulting from a low-protein
diet would have a demonstrable effect on renal function.
However, your hypothesis has not been addressed, to my
knowledge, in any of the studies of dietary influence on the rate
of progression in chronic renal insufficiency.
DR. PERRONE: To what extent does the increase in creatinine
secretion associated with worsened renal function affect the
secretion of uric acid?
DR. Bcx: the uric acid secretory pathway is distinctly
different from that which transports creatinine. The creatinine
pathway is probably a weak base transport system, since it is
interfered with by other weak bases (such as cimetidine and
trimethoprim) [45]. 'I'hcrefore, there should be no interaction
from the weak acid urate. in fact, the uric acid secretion and
excretion per ncphron, as estimated by the fractional excretion
of urate, is actually increased in chronic renal failure; some
have taken this as evidence for a uremic uricosuric factor [431.
DR. VINCENT CANZANELLO (Division of Nephroloy,
NEMCH): Are there any reports using serial renal biopsies in
patients with gout to help separate progressive nephrosclerosis
from interstitial disease?
DR. BECK: No, not that I know of.
Reprint requests to Dr. L. Beck (11/). Philadelphia Veterans Admin-
istration Medical Center, Uni,'ersit' and Wood/and A venues, Philadel-
phia, Pennsylvania /9/04, USA
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